Franklin Resources Inc. Purchases 3,620 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Franklin Resources Inc. boosted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 13.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,625 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,620 shares during the quarter. Franklin Resources Inc.’s holdings in Collegium Pharmaceutical were worth $1,164,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System boosted its position in shares of Collegium Pharmaceutical by 1.9% in the second quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock valued at $531,000 after acquiring an additional 300 shares during the period. TD Private Client Wealth LLC raised its stake in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares in the last quarter. Foundry Partners LLC boosted its holdings in Collegium Pharmaceutical by 3.3% in the 3rd quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 509 shares during the period. CWM LLC grew its position in shares of Collegium Pharmaceutical by 97.5% during the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 736 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 792 shares during the period.

Collegium Pharmaceutical Trading Down 1.3 %

Shares of COLL stock opened at $29.11 on Friday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a fifty-two week low of $28.75 and a fifty-two week high of $42.29. The company has a market cap of $938.80 million, a PE ratio of 12.55 and a beta of 0.80. The stock’s fifty day moving average price is $31.53 and its two-hundred day moving average price is $34.18.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on COLL shares. HC Wainwright increased their price target on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.